Worth reading
3Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Items stated in the management plan
Publication date7 October 2026
This document does not state the plan name, plan period, or numerical targets.
Key initiatives
01Promoting drug development using proprietary formulation technologies
02Aiming to sustainably enhance corporate value through the creation of innovative pharmaceuticals
| Item | Details |
|---|---|
| Key initiatives | Promoting drug development using proprietary formulation technologies, Aiming to sustainably enhance corporate value through the creation of innovative pharmaceuticals |
| Publication date | 7 October 2026 |
Items this document does not state (23)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for the market segment change was provided. However, the company explained that it would not change its commitment to growth or its research and development policy.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.